Navigation Links
Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
Date:5/17/2012

er than 7 days or neutropenia with a fever, your next dose of HALAVEN should be delayed and reduced. Severe neutropenia occurred in 57% (287/503) of patients who received HALAVEN and lasted more than 1 week in 12% (62/503) of patients. Neutropenia with a fever occurred in 5% (23/503) of patients; 2 patients died from complications of neutropenia with a fever.  Neutropenia with a fever can result in serious infections that could lead to hospitalization or death. Call your healthcare provider immediately if you have any of the following symptoms; fever (temperature above 100.5 degrees F), chills, coughing, burning or pain when you urinate.

Nerve Disorders (Peripheral Neuropathy)

HALAVEN can cause numbness, tingling, or burning in your hands and feet (peripheral neuropathy). You should be monitored closely for signs of neuropathy.  If you develop severe neuropathy, treatment with HALAVEN should be delayed until the neuropathy improves and the next dose of HALAVEN should be reduced. Severe peripheral neuropathy occurred in 8% (42/503) of patients who received HALAVEN. Neuropathy lasting more than one year occurred in 5% of patients. Twenty-two percent (109/503) of patients developed a new or worsening neuropathy that had not recovered after an average of 269 days.  Peripheral neuropathy was the most common side effect that caused patients to stop receiving HALAVEN.

Pregnancy and Nursing

HALAVEN may harm your unborn baby. Avoid becoming pregnant while you are receiving HALAVEN. Tell your healthcare provider right away if you become pregnant or think you are pregnant while you are receiving HALAVEN. You and your healthcare provider should decide if you will receive HALAVEN or breastfeed. You should not do both.

Heartbeat Changes

HALAVEN can cause changes in your heartbeat (called QTc prolongation). This can cause irregular heartbeats that may lead to death. Your healthcare provider will de
'/>"/>

SOURCE Eisai Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
2. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
3. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
4. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
5. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
6. Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute
7. Eisai Inc. and the Alzheimers Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimers Disease
8. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
9. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
11. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... TAMPA, Fla. , Jan. 23, 2015  iMD Companies, Inc. ... plan to increase market share and grab a foothold in ... with influence, production capabilities and a presence in the sector, ... them facilitate the growth of hemp and medical marijuana, iMD ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... BOULDER, Colo. , Jan. 22, 2015  BiOptix is ... Klakamp as Vice President of Chemistry and Biochemistry. Scott ... Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course ... and development. "Scott is a nationally recognized ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... YONKERS, N.Y., Sept. 27, 2011 As a result ... that could be dangerous to their health, according to ... Americans who currently take a prescription medicine told pollsters ... a doctor,s visit or medical procedure, declining tests, or ...
... Pa., Sept. 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE ... development of synthetic immunogens against cancers and infectious diseases, ... Research and Development Agreement (CRADA) with the United States ... Plum Island Animal Disease Center. This collaboration will evaluate ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Reddy’s, the Indian pharma giant has decided to join hands ... trials of a new fixed dose combination or “polypills” to ... four drugs- aspirin, statin(to reduce cholesterol) and two drugs to ... pill when it comes to safety and its effectiveness when ...
... Mars as believed earlier but ‘very liquid, very flowing water’//. ... on Mars," said Ken Edgett, a scientist with Malin Space ... about liquid water that is present on Mars right now.” ... a satellite in orbit around Mars support this assumption. NASA ...
... cancer patients who are still young, and have completed ... stipulated //two years, post-treatment, to plan a family, suggest ... advised to wait for two years before contemplating conception, ... ,Angela Ives of the University of Western ...
... the first in Australia to apply for a licence to ... stem cell research will be a cure for diabetes, with ... years. ,A Legislation has been passed by the ... cloning, which had paved the way for sceintists to enter ...
... with a finding published in the journal Psychology of Addictive ... alcohol, and cigarettes in solitude, tend to develop behavioral and ... harder time quitting, as opposed to those who do so, ... results stem from a study spreading over nine years and ...
... skin of visitors' feet is turning into an intriguing experience ... of Turkish spa fish, members of the garra rufa species, ... spot at the Underwater World attraction., ,The reflexologists massage ... by the fish., ,It costs $22 for a 40-minute ...
Cached Medicine News:Health News:A Combined Heart Pill-developed by Dr. Reddy’ 2
... U.S. and international engineering and design ... and Plating System* provides seamless integration ... use for open reduction internal fixational ... system works well beyond the standard, ...
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
... The CARDIA PDA Closure Device has been ... Patent Ductus Arteriosus. Introduced through standard venous ... and reliable method for the percutaneous closure ... from 2mm-10mm within the ductus.,An integral locking ...
Half pin skeletal traction pins with cove point....
Medicine Products: